Adverse effects: insomnia · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant showed no clear difference in adverse effects: insomnia compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: gastrointestinal upset · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant showed no clear difference in adverse effects: gastrointestinal upset compared with placebo (moderate certainty).
1 finding from 1 review
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic probably leads to lower global evaluation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, and excessive sleepiness · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic showed no clear difference in adverse effects: drowsiness, hypersomnia, and excessive sleepiness compared with placebo (low certainty).
1 finding from 1 review
Global evaluation · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant probably leads to lower global evaluation compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…
1 finding from 1 review
Intervention not reported
Severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 812(1 RCT)
The intervention showed no clear difference in severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants:… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1916(2 RCTs)
It is very uncertain whether the intervention changes ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2480(2 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 4818(4 RCTs)
The intervention probably leads to higher ACQ responders at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2821(3 RCTs)
The intervention showed no clear difference in ACQ responders at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 6 months ‐ TRIPLE vs DUAL№ of participants: 7881(5 RCTs)
The intervention may leads to higher ACQ responders at 6 months ‐ TRIPLE vs DUAL№ of participants: 7881(5… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2817(2 RCTs)
The intervention showed no clear difference in ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 2222(2 RCTs)
The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT)
The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1631(1 RCT)
The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 1727(2 RCTs)
The intervention showed no clear difference in severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants:… (moderate certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3982(3 RCTs)
It is very uncertain whether the intervention changes ACQ responders at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (very low certainty).
1 finding from 1 review
Intervention not reported
ACQ responders at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1089(1 RCT)
The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).
1 finding from 1 review